As a routine practice for all newly diagnosed breast cancer in pathology, the HER2 test strategy with a low cost-effectiveness ratio involves screening all newly diagnosed breast cancers with IHC testing (a screening test), and reflexing HER2 IHC score of 2 + for evaluation by FISH testing (as a confirmation/follow-up test) [17, 20]. The gene discussed is ERBB2; the disease is breast carcinoma.